Accès ouvert déclaré
2025
article
Neutralizing and binding antibodies are a correlate of risk of COVID-19 in the CoVPN 3008 study in people with HIV
Vimla Naicker, Philip Kotze, William Kilembe, Simpson Nuwamanya, Yacoob Vahed, Peter B. Gilbert, Jack Heptinstall, John Hural, Samantha Fry, Erica Andersen‐Nissen, Haajira Kaldine, Avi Kenny, Zaheer Hoosain, Taraz Samandari, James Peng, Prudence Kgagudi, April K. Randhawa, Bo Zhang, Zvavahera M. Chirenje, Eduan Wilkinson, Sufia Dadabhai, Jia Jin Kee, Kelly E. Seaton, Disebo Potloane, Dishiki Kalonji, Lindsay N. Carpp, Annet Nanvubya, Fatima Laher, Vongane Louisa Maluleke, Glenda Gray, Jamil Said, Humphrey Mwape, Margaret Yacovone, Walter Otieno, David C. Montefiori, Asa Tapley, Steve Innes, Tumelo Moloantoa, M. Juliana McElrath, Jackline Odhiambo, Rodney Dawson, Nigel Garrett, Aaron Hudson, Essack Mitha, Andreas H. Diacon, Melvin C. Kamanga, Mohammed Siddique Tayob, Nonhlanhla N. Mkhize, Laura Polakowski, Katherine Gill, Caroline Brackett, Mina C. Hosseinipour, Grace Mboya, Yunda Huang, Lawrence Corey, Azwidihwi Takalani, Philister Adhiambo Madiega, Anda Madikida, Sharana Mahomed, Kirsten McHarry, Anusha Nana, Zelda Punt, Georgia D. Tomaras, Sinead Delany‐Moretlwe, Priya Kassim, Siyu Heng, Sharlaa Badal‐Faesen, James G. Kublin, Barbarah Kawoozo, Elsje Louise Potgieter, Bert Le Roux, William Brumskine, Yutong Jin, Sheetal Kassim, Craig A. Magaret, Nyaradzo Mgodi, Soritha Coetzer, Ethel Kamuti, Jiani Hu, Jessica Andriesen, Penny L. Moore, Harriet Nuwagaba‐Biribonwoha, Katanekwa Njekwa, Peter Elyanu, Mookho Malahleha, Daniel J. Schuster, Craig Innes, Yashna Singh, Sheetal Sawant, Sinethemba Bhebhe, Yajna Duki, Mubiana Inambao, Marcella Sarzotti‐Kelsoe, Deo Wabwire, Manuel Villarán, Pamela Mda, Guido Ferrari, Tandile Modise, Linda‐Gail Bekker, Zhe Chen, Maphoshane Nchabeleng, Parth D. Shah, Dorothie van der Vendt, Moroesi Moerane, Leigh H. Fisher, Joseph Makhema
0Citations signalées — pas une note de qualité
1Institutions déclarées
1Pays d’affiliation déclarés
Résumé fourni par la source
People with HIV (PWH) are understudied in COVID-19 vaccine trials, leaving knowledge gaps on whether the identified immune correlates of protection also hold in PWH. CoVPN 3008 (NCT05168813) enrolled predominantly PWH and reported lower COVID-19 incidence for a Hybrid vs. Vaccine Group (baseline SARS-CoV-2-positive and one mRNA-1273 dose vs. negative and two doses). Using case-cohort sampling, antibody markers at enrolment (M0) and four weeks post-final vaccination (Peak) are assessed as immune correlates of COVID-19. For the Hybrid Group [n = 287 (195 PWH)], all M0 markers inversely correlate with COVID-19 through 230 days post-Peak, with 50% inhibitory dilution BA.4/5 neutralizing antibody titer (nAb-ID50 BA.4/5) the strongest and only independent correlate (HR per 10-fold increase=0.46, 95% CI 0.28, 0.75; P = 0.002). For the Vaccine Group [n = 115 (86 PWH)], Peak nAb-ID50 BA.4/5 correlates with reduced COVID-19 risk (1.9%, 1.1%, and 0.3% at titers 10, 100, and 1000 AU/ml) through 92, but not 165, days post-Peak. Using multivariable Cox analysis of binding and nAb, nAb titers predict COVID-19 in PWH. Two doses of a 100-µg Ancestral strain mRNA vaccine in baseline-SARS-CoV-2-negative individuals elicit sufficient cross-reacting Omicron antibodies to reduce COVID-19 incidence for 90 days post-Peak, but viral evolution and waning antibodies abrogate this protection thereafter.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Contrôle bibliographique ouvert
La source scientifique ouverte est momentanément indisponible.
Institutions déclarées
Une affiliation ne permet pas de déduire la nationalité d’un auteur.
Sujets associés
SARS-CoV-2 and COVID-19 ResearchHepatitis C virus researchVaccine Coverage and Hesitancy